GlaxoSmithKline (GSK) is a global pharmaceutical company with a diversified portfolio of biologics, small molecules and consumer healthcare products. In Oncology GSK’s pipeline is focused on immuno-oncology, cell therapy, cancer epigenetics and synthetic lethality. The company was formed in 2000 as a result of merger between GlaxoWellcome plc and SmithKline Beecham.
- In Dec 2020, Surface Oncology (Nasdaq: SURF) out license worldwide development and commercial rights of its preclinical program SRF813, a fully human IgG1 antibody targeting PVRIG (also known as CD112R), an inhibitory protein expressed on natural killer cells (NK cells) and T cells to GlaxoSmithKline. Under the terms, GSK paid an $85 Mn in upfront payment, in addition, Surface Oncology may receive up to an additional $730 Mn in future milestone payments, along with royalties on global net sales.
- In Feb 2020, Immatics Biotechnologies and GSK, partner to develop novel adoptive cell therapies, under the terms GSK obtained the access to two Immatics TCR-T programs, while Immatics will receive an upfront payment of 45 Mn € (~$50 Mn) for two initial programs and is eligible to receive over $550 Mn in development, regulatory and commercial milestone payments for each product as well as additional royalty payments.
- In Oct 2019, GlaxoSmithKline signs 5 year research collaboration with Lyell Immunopharma to combine Glaxo’s cell and gene therapy programs with Lyell’s technology that aims to improve the function and “fitness” of T cells in the hope of warding off relapses stemming from T-cell exhaustion in solid tumors. Financial terms remains undisclosed.
- In Feb 2019, Merck KGaA entered a global strategic alliance with GlaxoSmithKline (GSK) to jointly develop and commercialize the investigational bifunctional fusion protein, bintrafusp alfa (M7824). Under the terms Merck KGaA, received an upfront payment of €300 Mn and is eligible for potential development milestone payments of up to €500 Mn triggered by data from the M7824 lung cancer program, plus future approval and commercial milestones of up to €2.9 billion for a total potential deal value of up to €3.7 billion. Both companies will jointly conduct development and commercialization with all profits and costs from the collaboration being shared equally on a global basis.
- In July, 2018, GlaxoSmithKline acquired GSK3377794 (GSK ‘794), an NY-ESO SPEAR T-cell therapy, and GSK assumes full responsibility for future research, development, and potential commercialization of this pioneering therapy, and Adaptimmune received the second option payment of £21.2 Mn from GSK.
- In Jan 2017, GSK nominated PRAME as a second target and, as a consequence of this option exercise for NY-ESO, GSK will have the right to nominate its third and fourth targets and Adaptimmune will take these programs through preclinical testing to IND. The agreement excludes targets on which work is already under way, including Adaptimmune’s wholly owned MAGE-A10, MAGE-A4, and AFP clinical programs and its active preclinical pipeline. Earlier, in June 2014, Adaptimmune and GSK collaborate to develop up to five programs including the first program, NY-ESO. The terms of the agreement were expanded in February 2016 to accelerate development of NY-ESO SPEAR T-cell therapy toward registration trials in synovial sarcoma, to explore development in MRCLS and to enable combination studies.
- GlaxoSmithKline formed a collaboration with Telo Therapeutics to develop a novel precision medicine with the aim to reverse cancer cell immortality.
- In 2016, Zymeworks signed new agreement with GSK to develop novel bi-specific antibodies using Azymetric™ drug discovery platform. Zymeworks received upfront & preclinical payments of up to USD$36 Mn and up to USD$152 Mn in development and clinical milestone payments, along with commercial sales milestone payments of up to USD$720 Mn, and royalties on sales.
- In 2015, Zymeworks signed agreement with GlaxoSmithKline (GSK) to develop novel Fc-engineered monoclonal and bi-specific antibody therapeutics, using Zymeworks’ Effector Function Enhancement and Control Technology (EFECT™) platform. Under the terms, GSK will have the right to develop a minimum of 4 products across multiple disease areas, and Zymeworks will be eligible to receive pre-clinical, clinical, and commercial milestones of up to USD$110 Mn for each product, as well as tiered sales royalties.
- In Mar 2015, Novartis completed the acquisition of GSK oncology products for a USD 14.5 billion payment and up to USD 1.5 billion contingent on a development milestone. Under the terms, Novartis acquired the worldwide marketing rights of GSK three oncology approved drugs – Votrient, Tafinar and Mekinist. Additional products included in the transaction include Tykerb® for HER2+ metastatic breast cancer, Arzerra® in chronic lymphocytic leukemia, and Promacta® for thrombocytopenia. Also, Novartis have an opt-in rights for GSK’s current and future oncology R&D pipeline, which could be a source of new compounds and new targets. Sales of the acquired GSK oncology products in 2013 were approximately USD 1.6 billion.
- In 2014, TESARO (now GlaxoSmithKline) and Anaptysbio entered into an exclusive, worldwide license agreement and immuno-oncology antibody collaboration under which Anaptysbio granted exclusive rights to GSK to develop and commercialize four AnaptysBio generated antibody product candidates including anti-PD-1 antibody (Dostarlimab, GSK4057190A), anti-TIM-3 antibody (Cobolomab, GSK4069889A), anti-LAG-3 Antibody (GSK4074386) and an anti-PD-1/LAG-3 Bispecific antibody.
- In 2013, Immunocore and GSK announced research collaboration to develop multiple novel cancer targets using Immunocore’s ImmTAC technology. Under the terms, Immunocore to receive up to a total of £142 Mn in pre-clinical milestone payments, with further additional, up to £200 Mn in development and commercial milestone payments, along-with up to double digit royalties. Immunocore will be responsible for all pre-clinical development and for the initial clinical trial in patients for the first two program. GSK will be responsible for the remaining development and commercialization of the products.
- In Jun 2012, TESARO in-licensed Niraparib/MK-4827 from Merck.
- In Apr 2012, GSK entered into a collaborative research and development agreement with Chiome Biosciences for its proprietary ADLib® system for cancer drug discovery.
Page 2 of 3
